An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.
An interim analysis of real-world outcomes collected from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with lanreotide (Somatuline) depot demonstrated that treatment with the somatostatin analog was effective in disease control. The analysis, presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, also found that most patients were satisfied with the treatment.
At least half of NETs—rare and often slow-growing forms of cancer arising from the endocrine system—originate in the small-bowel, colon, stomach, or pancreas, and are collectively known as GEP-NETS. In December 2014, lanreotide gained FDA approval for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs.
The analysis of the treatment followed 50 patients aged 18 and older who had locally-advanced or metastatic disease, well-differentiated NET, were initiating or previously treated with lanreotide depot, and had measurable disease. The study also took into account Eastern Cooperative Oncology Group Performance Status (ECOG-PS), which assesses how a patient's disease is progressing, assesses how the disease affects the daily living abilities of the patient, and determines appropriate treatment and prognosis. Patients included in the study had scores of 0 to 2, ranging from fully active to capable of all self-care but unable to carry out any work activities.
Patients were treated with 120 mg of subcutaneous lanreotide depot every 28 days and were examined every 6 months for evaluation of clinically defined outcomes based on disease progression an overall survival (OS), as well as symptoms (flushing/diarrhea), treatment satisfaction, and adverse events.
At 1-year follow up, the median age was 65, 84% of patients were Caucasion, 96% had an ECOG-PS of 0 or 1, and 36% had octreotide long-acting release experience prior to the study. Progression-free survival was 92% (95% CI: 79-97) and OS was 96% (95% CI: 84-99). There was largely no change in flushing or diarrhea, and more than 80% of patients reported still being satisfied with the treatment.
The main reasons for discontinuing treatment were disease progression (10%) and adverse events (4%). The main adverse events reported were nausea (6%), fatigue (4%), and abdominal pain (4%).
Reflecting on the analysis, which provides the first prospectively collected real-world outcomes of patients treated with lanreotide depot for GEP-NETs, the researchers wrote, “Interim results suggest lanreotide depot is effective in disease control and most patients are satisfied with their treatment.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More